Boosters for adeno-associated virus (AAV) vector (r)evolution

Joanna Szumska1, Dirk Grimm2

  • 1Department of Infectious Diseases/Virology, Section Viral Vector Technologies, Medical Faculty, University of Heidelberg, Heidelberg, Germany; BioQuant Center and Center for Integrative Infectious Diseases Research (CIID), University of Heidelberg, Heidelberg, Germany.

Cytotherapy
|August 23, 2022
PubMed
Summary

New methods accelerate the evolution of adeno-associated virus (AAV) capsids for gene therapy. These innovative techniques enhance the development of AAV vectors, driving advancements in genetic medicine.

Related Concept Videos